Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 2.4% – Should You Sell?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP)’s share price traded down 2.4% during mid-day trading on Friday . The stock traded as low as $11.57 and last traded at $12.03. 13,861 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 53,537 shares. The stock had previously closed at $12.33.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

The firm’s 50-day moving average price is $13.36 and its two-hundred day moving average price is $14.40. The company has a quick ratio of 2.21, a current ratio of 2.21 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $64.24 million, a PE ratio of -4.21 and a beta of -0.50.

Institutional Trading of Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of the business. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics in the third quarter worth $140,000. Geode Capital Management LLC lifted its stake in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares in the last quarter. State Street Corp boosted its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Finally, Marshall Wace LLP purchased a new position in Coeptis Therapeutics during the 4th quarter valued at about $259,000. Hedge funds and other institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.